300 related articles for article (PubMed ID: 27005770)
1. Portfolio of prospective clinical trials including brachytherapy: an analysis of the ClinicalTrials.gov database.
Cihoric N; Tsikkinis A; Miguelez CG; Strnad V; Soldatovic I; Ghadjar P; Jeremic B; Dal Pra A; Aebersold DM; Lössl K
Radiat Oncol; 2016 Mar; 11():48. PubMed ID: 27005770
[TBL] [Abstract][Full Text] [Related]
2. The American College of Radiology and the American Brachytherapy Society practice parameter for the performance of low-dose-rate brachytherapy.
Viswanathan AN; Erickson BA; Ibbott GS; Small W; Eifel PJ
Brachytherapy; 2017; 16(1):68-74. PubMed ID: 28109633
[TBL] [Abstract][Full Text] [Related]
3. Low-dose rate brachytherapy for men with localized prostate cancer.
Peinemann F; Grouven U; Hemkens LG; Bartel C; Borchers H; Pinkawa M; Heidenreich A; Sauerland S
Cochrane Database Syst Rev; 2011 Jul; (7):CD008871. PubMed ID: 21735436
[TBL] [Abstract][Full Text] [Related]
4. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
[TBL] [Abstract][Full Text] [Related]
5. High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer.
Wang X; Liu R; Ma B; Yang K; Tian J; Jiang L; Bai ZG; Hao XY; Wang J; Li J; Sun SL; Yin H
Cochrane Database Syst Rev; 2010 Jul; (7):CD007563. PubMed ID: 20614461
[TBL] [Abstract][Full Text] [Related]
6. Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer.
Zaorsky NG; Den RB; Doyle LA; Dicker AP; Hurwitz MD
Expert Rev Med Devices; 2013 Nov; 10(6):751-63. PubMed ID: 24195459
[TBL] [Abstract][Full Text] [Related]
7. Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials.
Peinemann F; Grouven U; Bartel C; Sauerland S; Borchers H; Pinkawa M; Heidenreich A; Lange S
Eur Urol; 2011 Nov; 60(5):881-93. PubMed ID: 21763066
[TBL] [Abstract][Full Text] [Related]
8. Dosimetric comparison between treatment plans of patients treated with low-dose-rate vs. high-dose-rate interstitial prostate brachytherapy as monotherapy: Initial findings of a randomized clinical trial.
Major T; Polgár C; Jorgo K; Stelczer G; Ágoston P
Brachytherapy; 2017; 16(3):608-615. PubMed ID: 28325472
[TBL] [Abstract][Full Text] [Related]
9. Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?
Zaorsky NG; Doyle LA; Hurwitz MD; Dicker AP; Den RB
Expert Rev Anticancer Ther; 2014 Jan; 14(1):39-50. PubMed ID: 24124755
[TBL] [Abstract][Full Text] [Related]
10. Under-utilisation of high-dose-rate brachytherapy boost in men with intermediate-high risk prostate cancer treated with external beam radiotherapy.
Ong WL; Evans SM; Millar JL
J Med Imaging Radiat Oncol; 2018 Apr; 62(2):256-261. PubMed ID: 29271056
[TBL] [Abstract][Full Text] [Related]
11. [High dose rate brachytherapy].
Aisen S; Carvalho HA; Chavantes MC; Esteves SC; Haddad CM; Permonian AC; Taier Mdo C; Marinheiro RC; Feriancic CV
Rev Hosp Clin Fac Med Sao Paulo; 1992; 47(3):121-4. PubMed ID: 1340584
[TBL] [Abstract][Full Text] [Related]
12. Clinical indications for brachytherapy.
Erickson B; Wilson JF
J Surg Oncol; 1997 Jul; 65(3):218-27. PubMed ID: 9236932
[TBL] [Abstract][Full Text] [Related]
13. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy.
Georg D; Hopfgartner J; Gòra J; Kuess P; Kragl G; Berger D; Hegazy N; Goldner G; Georg P
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):715-22. PubMed ID: 24521685
[TBL] [Abstract][Full Text] [Related]
14. 192Ir or 125I prostate brachytherapy as a boost to external beam radiotherapy in locally advanced prostatic cancer: a dosimetric point of view.
Nickers P; Thissen B; Jansen N; Deneufbourg JM
Radiother Oncol; 2006 Jan; 78(1):47-52. PubMed ID: 16216365
[TBL] [Abstract][Full Text] [Related]
15. Second primary malignancies after radiotherapy including HDR (252)Cf brachytherapy for cervical cancer.
Samerdokiene V; Valuckas KP; Janulionis E; Atkocius V; Rivard MJ
Brachytherapy; 2015; 14(6):898-904. PubMed ID: 26194049
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive analysis of brachytherapy clinical trials over the past 15 years.
Odei BC; Boothe D; Lloyd S; Gaffney DK
Brachytherapy; 2016; 15(6):679-686. PubMed ID: 27475486
[TBL] [Abstract][Full Text] [Related]
17. High-dose-rate brachytherapy and external-beam radiotherapy for hormone-naïve low- and intermediate-risk prostate cancer: a 7-year experience.
Aluwini S; van Rooij PH; Kirkels WJ; Jansen PP; Praag JO; Bangma CH; Kolkman-Deurloo IK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1480-5. PubMed ID: 22285661
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of patients with localized and locally advanced prostate cancer undergoing high-dose-rate brachytherapy with external-beam radiotherapy at our institute.
Makino T; Mizokami A; Namiki M
Anticancer Res; 2015 Mar; 35(3):1723-8. PubMed ID: 25750334
[TBL] [Abstract][Full Text] [Related]
19. American Brachytherapy Task Group Report: A pooled analysis of clinical outcomes for high-dose-rate brachytherapy for cervical cancer.
Mayadev J; Viswanathan A; Liu Y; Li CS; Albuquerque K; Damato AL; Beriwal S; Erickson B
Brachytherapy; 2017; 16(1):22-43. PubMed ID: 28109631
[TBL] [Abstract][Full Text] [Related]
20. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
